Lei Huijia, Zhu Sixiang, Yang Jing, Lai Youqing, Wang Zijing
Department of Otorhinolaryngology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Front Neurol. 2025 Jul 18;16:1631296. doi: 10.3389/fneur.2025.1631296. eCollection 2025.
The key to treating Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) by mandibular advancement device (MAD) lies in determining the optimal mandibular advancement, but current subjective titration methods are time-consuming and have poor compliance. Therefore, this study proposes an objective titration scheme based on a Remotely Contactless Intelligent Sleep Monitoring System (RCISMS) to optimize the MAD titration process, improve treatment efficiency, and enhance patient comfort.
This study enrolled 60 OSAHS patients, randomly divided into a RCISMS-guided titration group ( = 30) and a subjective titration group ( = 30). Patients in the RCISMS-guided titration group used RCISMS at home to monitor AHI, which was transmitted in real-time to clinicians online for remote guidance on MAD adjustments. The subjective titration group required adjustments based on patient self-reports during clinic visits. The primary endpoint was the reduction in AHI, and secondary endpoints included titration time efficiency and improvements in subjective symptoms (Epworth Sleepiness Scale, Snoring Scale).
Both RCISMS-guided and subjective titration significantly reduced AHI (by 73.7 and 69.0%, respectively), with no significant difference in final AHI levels between the two groups ( = 0.0828). RCISMS-guided titration significantly shortened the titration cycle (27.00 ± 2.12 days vs. 45.07 ± 8.25 days, < 0.0001), saving 40.01% of the time compared to subjective titration. There were no significant differences between the two groups in ESS reduction (RCISMS group 3.0 ± 1.2 vs. subjective titration group 3.3 ± 1.5, = 0.3943) and Snoring VAS scores reduction (RCISMS group 3.8 ± 0.5 vs. subjective titration group 3.9 ± 0.5, = 0.3306).
The RCISMS-guided MAD titration scheme can achieve the same therapeutic effect as traditional subjective titration methods in a shorter time, while reducing the number of patient visits, improving treatment convenience and compliance, and demonstrating significant potential for clinical application.
采用下颌前移装置(MAD)治疗阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的关键在于确定最佳的下颌前移量,但目前的主观滴定方法耗时且依从性差。因此,本研究提出一种基于远程非接触式智能睡眠监测系统(RCISMS)的客观滴定方案,以优化MAD滴定过程,提高治疗效率,并增强患者舒适度。
本研究纳入60例OSAHS患者,随机分为RCISMS引导滴定组(n = 30)和主观滴定组(n = 30)。RCISMS引导滴定组的患者在家中使用RCISMS监测呼吸暂停低通气指数(AHI),该数据实时传输给临床医生以进行MAD调整的远程指导。主观滴定组则需要根据患者在门诊就诊时的自我报告进行调整。主要终点是AHI的降低,次要终点包括滴定时间效率和主观症状(爱泼华嗜睡量表、打鼾量表)的改善。
RCISMS引导滴定和主观滴定均显著降低了AHI(分别降低了73.7%和69.0%),两组最终的AHI水平无显著差异(P = 0.0828)。RCISMS引导滴定显著缩短了滴定周期(27.00 ± 2.12天 vs. 45.07 ± 8.25天,P < 0.0001),与主观滴定相比节省了40.01%的时间。两组在爱泼华嗜睡量表评分降低方面(RCISMS组3.0 ± 1.2 vs. 主观滴定组3.3 ± 1.5,P = 0.3943)和打鼾视觉模拟评分降低方面(RCISMS组3.8 ± 0.5 vs. 主观滴定组3.9 ± 0.5,P = 0.3306)均无显著差异。
RCISMS引导的MAD滴定方案能在更短时间内达到与传统主观滴定方法相同的治疗效果,同时减少患者就诊次数,提高治疗便利性和依从性,具有显著的临床应用潜力。